Lilly adds "slimming drugs": announced an investment of US$5.3 billion to expand production capacity
Source: Zhao Ying from Wall Street
This is the largest investment in the company's nearly 150-year history.
According to media reports on Fridayrouletteevolution, Lilly Company maderouletteevolutionIn a major decision, it announced an investment of US$5.3 billion to increase the production capacity of tirzepatide, a key ingredient in its weight loss and diabetes injections.
This investment not only adds to existing plans, but is also the largest investment in the company's nearly 150-year history.
This will expand its manufacturing facility in Indiana, which makes tirzepatide, the active ingredient of Zepbound diet drug and diabetes blockbuster Mounjaro.
